| SHARE BASED COMPENSATION |
Note
10: - SHARE BASED COMPENSATION
|
a. |
A summary of the stock option activity under the Company’s equity plans during the nine months ended
September 30, 2025 is as follows: |
| |
|
Outstanding share options
|
|
| Weighted-average exercise price ($) |
|
| Weighted average remaining contractual life (years) |
|
| Aggregate intrinsic value ($ in thousands) |
|
| Options: |
| |
|
| |
|
| |
|
| |
|
| Outstanding as of December 31, 2024 |
| |
4,590,375 |
|
| |
4.62 |
|
| |
5.87 |
|
| |
1,364,975 |
|
| |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| Granted |
| |
360,000 |
|
| |
1.31 |
|
| |
6.04 |
|
| |
- |
|
| Forfeited |
| |
(14,664 |
) |
| |
4.14 |
|
| |
- |
|
| |
- |
|
| Expired |
| |
(272,040 |
) |
| |
7.28 |
|
| |
- |
|
| |
- |
|
| Exercised |
| |
(360,601 |
) |
| |
1.22 |
|
| |
- |
|
| |
- |
|
| Outstanding as of September 30, 2025 |
| |
4,303,070 |
|
| |
4.47 |
|
| |
5.54 |
|
| |
988,581 |
|
| |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| Exercisable as of September 30, 2025 |
| |
3,593,284 |
|
| |
4.77 |
|
| |
4.93 |
|
| |
867,261 |
|
| |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| Options available for future grants |
| |
1,993,005 |
|
| |
|
|
| |
|
|
| |
|
|
A summary of the
Company’s RSUs activity during the nine months ended September 30, 2025 is as follows:
| |
|
Numbers of RSUs |
|
| RSUs: |
|
|
|
| Outstanding as of December 31, 2024 |
|
|
4,913,123 |
|
| Granted |
|
|
2,426,337 |
|
| Forfeited |
|
|
(264,466 |
) |
| Vested |
|
|
(3,841,680 |
) |
| Outstanding as of September 30, 2025 |
|
|
3,233,314 |
|
The following table
set forth the parameters used in the computation of the options compensation to employees:
| |
|
Nine months ended September 30,
|
|
| |
| 2025 |
|
| 2024 |
|
| |
| |
|
| |
|
| Expected term, in years |
| |
5.81 |
|
| |
6.11 |
|
| Expected volatility |
| |
51.88 |
% |
| |
51.75 |
% |
| Risk-free interest rate |
| |
3.64 |
% |
| |
4.23 |
% |
| Expected dividend yield |
| |
0 |
% |
| |
0 |
% |
|
c. |
The following table presents share-based compensation expense for employees included in the Company’s
consolidated statements of operations: |
| |
|
Nine months ended September 30,
|
|
| |
|
2025 |
|
|
2024 |
|
| |
|
|
|
|
|
|
| Research and development |
|
|
5,042 |
|
|
|
7,731 |
|
| Sales and marketing |
|
|
1,320 |
|
|
|
1,845 |
|
| General and administrative |
|
|
1,088 |
|
|
|
1,601 |
|
| Cost of revenues |
|
|
125 |
|
|
|
222 |
|
| |
|
|
|
|
|
|
|
|
| Total stock-based compensation expense |
|
|
7,575 |
|
|
|
11,399 |
|
Share-based
compensation expenses are not deductible for Israeli income tax purposes, and therefore the Company did not recognize any tax benefits
related to the share-based compensation for the nine months ended September 30, 2025 and 2024.
During
the nine months ended September 30, 2025 and 2024, the Company recognized the total fair value of warrants issued to non-employee service
providers of $519 and $639, respectively.
|